Transcatheter Edge-to-Edge Repair Under Argatroban in IABP-Supported Acute Mitral Regurgitation With Suspected Heparin-Induced Thrombocytopenia Authors: Yurie Yoshikado, Takahiro Sawada, Hiroyuki Shimoura, Jun Mukai, Yuya Terao, Makoto Kadotani, Yoshio Onishi, Ken-ichi Hirata Published: 2026 ABSTRACT BackgroundHeparin-induced thrombocytopenia (HIT) is a prothrombotic immune-mediated complication that complicates cardiac surgery because cardiopulmonary bypass requires systemic heparinization. We report a case of acute severe mitral regurgitation (MR) complicated by clinically suspected HIT, in which conventional surgical repair was not feasible.Case SummaryA 59-year-old man presented with acute severe MR due to chordal rupture and developed cardiogenic shock requiring intra-aortic balloon pump support. While awaiting surgery, his platelet count decreased from 262,000/μL to 23,000/μL. The 4Ts score was 6, and PF4/heparin antibody testing was positive, supporting clinically suspected HIT. Because cardiopulmonary bypass requiring systemic heparinization was considered prohibitively high risk, M-TEER was performed under continuous argatroban infusion. Two PASCAL Ace implants were successfully deployed, reducing MR from severe to trivial without thrombotic or bleeding complications. The patient recovered rapidly with immediate IABP removal and early extubation.DiscussionThis case demonstrates that M-TEER under argatroban anticoagulation can be a feasible alternative when conventional surgery is precluded by suspected HIT and the anticipated challenges of anticoagulation during cardiopulmonary bypass.Take-Home MessageM-TEER under argatroban may serve as a rescue strategy for critically ill patients with acute severe MR and suspected HIT when surgical management is not feasible. History of Presentation A 59-year-old man presented with progressive dyspnea for 4 days. He was initially treated for presumed severe pneumonia with antibiotics and corticosteroids; however, his respiratory failure did not improve, necessitating endotracheal intubation and mechanical ventilation. Chest radiography and computed tomography suggested pulmonary edema rather than infection (Figure 1), and echocardiography revealed severe mitral regurgitation (MR) due to P2 prolapse caused by chordal rupture (Figure 2A). The left ventricle was not dilated, with a left ventricular end-diastolic diameter of 47.7 mm, and left ventricular ejection fraction was preserved at 65%, findings consistent with acute MR. The estimated tricuspid regurgitation pressure gradient was 76 mm Hg, indicating significant pulmonary hypertension. He was subsequently referred to the cardiology service.Figure 1Chest Radiography and Computed Tomography Demonstrating Bilateral Pulmonary Congestion Consistent With Pulmonary Edema Rather Than InfectionFigure 2Preprocedural Echocardiographic Findings(A) Transthoracic echocardiographic apical 4-chamber view demonstrating severe eccentric mitral regurgitation caused by chordal rupture involving the P2 segment. (B) Transesophageal echocardiography demonstrating severe eccentric mitral regurgitation caused by chordal rupture involving the P2 segment. Chest Radiography and Computed Tomography Demonstrating Bilateral Pulmonary Congestion Consistent With Pulmonary Edema Rather Than Infection Preprocedural Echocardiographic Findings (A) Transthoracic echocardiographic apical 4-chamber view demonstrating severe eccentric mitral regurgitation caused by chordal rupture involving the P2 segment. (B) Transesophageal echocardiography demonstrating severe eccentric mitral regurgitation caused by chordal rupture involving the P2 segment. Past Medical History The patient had a history of hypertension without medical treatment and a 40-pack-year smoking history. There was no history of cardiovascular disease. Investigations Electrocardiography demonstrated sinus rhythm at 93 beats/min without significant ST-segment abnormalities. Transesophageal echocardiography demonstrated posterior leaflet prolapse caused by chordal rupture involving the P2 segment (Figure 2B). Coronary angiography revealed no significant coronary artery stenosis, and the patient was diagnosed with primary MR due to chordal rupture. Hemodynamic assessment with a Swan–Ganz catheter demonstrated a cardiac index of 2.1 L/min/m2 and a pulmonary capillary wedge pressure of 39 mm Hg, consistent with low cardiac output and severe pulmonary congestion. An intra-aortic balloon pump (IABP) was initiated for hemodynamic stabilization as a bridge to planned surgical mitral valve repair. Following transfer to the cardiology service, unfractionated heparin was initiated on hospital day 1 for venous thromboembolism prophylaxis. On hospital day 7, the platelet count decreased markedly from 262,000/μL to 23,000/μL, raising suspicion for heparin-induced thrombocytopenia (HIT). The 4 Ts score was 6, indicating a high clinical probability of HIT. A skin rash resembling erythema was observed on the lower leg, and subsequent ultrasonography confirmed deep vein thrombosis. Platelet factor 4 (PF4)/heparin antibody testing using a latex immunoassay revealed a value of 7.5 U/mL, further supporting clinically suspected HIT. Management Heparin was immediately discontinued, and anticoagulation was switched to argatroban. Argatroban was initiated at 0.7 μg/kg/min and titrated to maintain an activated partial thromboplastin time (aPTT) of 50 to 80 seconds. Because cardiopulmonary bypass for surgical mitral valve repair requires systemic heparinization, the treatment strategy was discussed by a multidisciplinary heart team. In addition to the need to avoid heparin, profound thrombocytopenia and the patient's critical condition requiring mechanical ventilation and IABP support rendered surgical intervention prohibitive. Furthermore, our institution had no previous experience with alternative anticoagulation during cardiopulmonary bypass. Therefore, transcatheter edge-to-edge mitral valve repair (M-TEER) was selected as an alternative strategy. On hospital day 13, M-TEER was performed using the PASCAL Precision system (Edwards Lifesciences) under continuous argatroban infusion at 1.2 μg/kg/min. Anticoagulation was primarily guided by aPTT, with activated clotting time (ACT) used as a supplementary parameter, which was maintained at approximately 260 seconds during the procedure. Given the potential for future surgical mitral valve repair after recovery from suspected HIT, a device strategy aimed at minimizing leaflet injury was considered, and a PASCAL Ace implant was selected. Two PASCAL Ace implants were successfully deployed at the prolapsed segment of the posterior leaflet, resulting in a marked reduction in MR from severe to trivial without thrombotic or bleeding complications (Figures 3A to 3C).Figure 3Transcatheter Edge-to-Edge Repair Under Argatroban Anticoagulation(A) Preprocedural transesophageal echocardiographic commissure view demonstrating severe mitral regurgitation before transcatheter edge-to-edge mitral valve repair. (B) Postprocedural transesophageal echocardiographic commissure view demonstrating marked reduction of mitral regurgitation after implantation of PASCAL Ace implants. (C) Three-dimensional transesophageal echocardiography after implantation of 2 PASCAL Ace implants demonstrating successful leaflet approximation with trivial residual mitral regurgitation. Transcatheter Edge-to-Edge Repair Under Argatroban Anticoagulation (A) Preprocedural transesophageal echocardiographic commissure view demonstrating severe mitral regurgitation before transcatheter edge-to-edge mitral valve repair. (B) Postprocedural transesophageal echocardiographic commissure view demonstrating marked reduction of mitral regurgitation after implantation of PASCAL Ace implants. (C) Three-dimensional transesophageal echocardiography after implantation of 2 PASCAL Ace implants demonstrating successful leaflet approximation with trivial residual mitral regurgitation. The IABP was removed immediately after the procedure, and the patient was successfully extubated the following day. Follow-Up After the procedure, the patient showed rapid hemodynamic improvement. The IABP was removed immediately after M-TEER, and the patient was successfully extubated the following day. However, delayed platelet recovery may reflect multifactorial platelet consumption associated with residual deep vein thrombosis and critical illness. During this period, anticoagulation with argatroban was maintained with aPTT of 50 to 80 seconds. Under continued anticoagulation therapy, the patient remained hemodynamically stable without recurrence of heart failure. Gradual recovery of platelet counts was observed during the clinical course. On hospital day 46, the platelet count reached 93 × 103/μL, allowing a switch of anticoagulation therapy to oral rivaroxaban. The patient was subsequently discharged home on hospital day 53. Discussion HIT is an immune-mediated adverse reaction characterized by thrombocytopenia and a paradoxical prothrombotic state caused by antibodies against PF4–heparin complexes. The incidence of HIT is estimated to range from 0.1% to 5% among patients exposed to heparin, and it is associated with a high risk of venous and arterial thrombosis if not promptly recognized and treated.1,2 The present case illustrates a rare and clinically challenging scenario in which acute severe primary MR due to chordal rupture coexisted with suspected HIT. Acute MR represents a distinct clinical entity characterized by abrupt increases in left atrial pressure and pulmonary congestion, often leading to rapid hemodynamic deterioration and the need for urgent intervention. Current guidelines recommend early surgical mitral valve repair in patients with acute severe primary MR when feasible.3 However, this standard strategy is fundamentally dependent on cardiopulmonary bypass with systemic heparinization. In patients with active or suspected HIT, systemic heparinization is generally avoided because of the risk of catastrophic thrombotic complications. Although alternative anticoagulation strategies using direct thrombin inhibitors such as argatroban or bivalirudin have been reported during cardiopulmonary bypass, these approaches remain technically demanding and require careful anticoagulation monitoring. The Society of Thoracic Surgeons guidelines consider bivalirudin a reasonable alternative anticoagulant for cardiopulmonary bypass in patients with HIT (Class IIa);4 however, both bivalirudin and argatroban lack specific reversal agents, which may complicate hemostatic management after separation from cardiopulmonary bypass.5,6 Consequently, the use of nonheparin anticoagulation during cardiopulmonary bypass requires substantial expertise and remains challenging even in experienced centers. In the present case, the inherent complexity of cardiopulmonary bypass using nonheparin anticoagulants, together with the absence of institutional experience and the patient's critical condition, made conventional surgical intervention prohibitively high risk. Severe respiratory failure requiring mechanical ventilation and hemodynamic instability necessitating IABP support indicated a critically ill state. Taken together, these factors increased the anticipated perioperative risk and limited the feasibility of conventional surgical intervention. In this context, M-TEER was considered an individualized treatment strategy given the exceptional circumstances of suspected HIT and the anticipated challenges of anticoagulation management during cardiopulmonary bypass. M-TEER has emerged as an established treatment option for severe MR in patients at high or prohibitive surgical risk. Randomized trials such as EVEREST II (Endovascular Valve Edge-to-Edge Repair Study II) and COAPT (Cardiovascular Outcomes Assessment of the MitraClip Percutaneous Therapy for Heart Failure Patients with Functional Mitral Regurgitation) have demonstrated the safety and efficacy of this approach in selected populations, primarily involving chronic MR.7,8 However, patients with acute MR due to chordal rupture were largely excluded from these studies, and evidence supporting the use of M-TEER in acute primary MR remains limited. Nevertheless, several case reports and small series have suggested that M-TEER may provide rapid hemodynamic stabilization in selected patients with acute severe MR who are considered poor surgical candidates.9 Despite the limited evidence, the pathophysiological rationale for M-TEER in acute MR is compelling. By approximating the mitral leaflets and reducing the effective regurgitant orifice area, M-TEER can rapidly decrease regurgitant volume, improve forward cardiac output, and reduce left atrial pressure. These effects are particularly beneficial in patients with acute pulmonary edema and hemodynamic compromise. In the present case, implantation of 2 PASCAL Ace implants at the prolapsed P2 segment resulted in a marked reduction in MR severity from severe to trivial, which was associated with rapid clinical improvement, including early extubation and prompt removal of IABP support. Importantly, the procedure was successfully completed despite profound thrombocytopenia and critical illness without thrombotic or bleeding complications. Another important aspect of this case is the feasibility of performing M-TEER under argatroban anticoagulation. Argatroban is a direct thrombin inhibitor with predictable pharmacokinetics and a short half-life, making it a reasonable alternative anticoagulant in patients with HIT. However, its use in structural heart interventions is not well established, and optimal anticoagulation strategies, including target ACT, have not been standardized. In this case, anticoagulation was primarily guided by aPTT, with ACT used as a supplementary procedural parameter maintained at approximately 260 seconds. This strategy allowed successful completion of M-TEER without device-related thrombosis or bleeding complications. The delayed recovery of platelet counts observed in this patient may reflect multifactorial platelet consumption associated with residual thrombosis and critical illness. Continued anticoagulation with argatroban until platelet recovery, followed by transition to a direct oral anticoagulant such as rivaroxaban, is consistent with current recommendations for the management of HIT-associated thrombosis and prevention of recurrent thrombosis during the recovery phase.5 This case also underscores the critical importance of a multidisciplinary heart team approach in managing complex patients with competing risks. The integration of expertise from cardiology, cardiac surgery, hematology, and critical care allowed for individualized decision-making that prioritized both procedural safety and hemodynamic stabilization. From a broader perspective, this case expands the potential role of M-TEER beyond its current evidence base. It suggests that M-TEER may serve as a feasible rescue strategy in patients with acute severe primary MR when conventional surgery is prohibitively high risk. Furthermore, it provides practical insight into the use of argatroban as an alternative anticoagulation strategy during structural heart interventions in patients with suspected HIT. Study limitations This report describes a single case, and the generalizability of these findings is inherently limited. In addition, the diagnosis of HIT was based on clinical probability and PF4/heparin antibody positivity without confirmatory functional testing. Furthermore, standardized anticoagulation protocols for structural heart interventions under argatroban have not been established, and optimal monitoring strategies require further investigation. Conclusions This case demonstrates that M-TEER under argatroban anticoagulation may serve as a feasible rescue strategy for critically ill patients with acute severe primary MR and clinically suspected HIT when conventional surgical management is prohibitively high risk.Take-Home Messages•Acute severe primary MR complicated by clinically suspected HIT poses a major therapeutic challenge because conventional surgical repair requiring systemic heparinization may be prohibitively high risk.•In this setting, M-TEER under argatroban anticoagulation may serve as a feasible rescue strategy for rapid hemodynamic stabilization.Visual SummaryClinical Course and Management Strategy of Acute Severe Primary Mitral Regurgitation Complicated by Clinically Suspected Heparin-Induced ThrombocytopeniaThe figure summarizes the multidisciplinary decision-making process leading to M-TEER under argatroban anticoagulation, resulting in rapid hemodynamic stabilization without thrombotic or bleeding complications. ACT = activated clotting time; aPTT = activated partial thromboplastin time; HIT = heparin-induced thrombocytopenia; IABP = intra-aortic balloon pump; MR = mitral regurgitation; M-TEER = transcatheter edge-to-edge mitral valve repair. Take-Home Messages •Acute severe primary MR complicated by clinically suspected HIT poses a major therapeutic challenge because conventional surgical repair requiring systemic heparinization may be prohibitively high risk.•In this setting, M-TEER under argatroban anticoagulation may serve as a feasible rescue strategy for rapid hemodynamic stabilization. •Acute severe primary MR complicated by clinically suspected HIT poses a major therapeutic challenge because conventional surgical repair requiring systemic heparinization may be prohibitively high risk. Acute severe primary MR complicated by clinically suspected HIT poses a major therapeutic challenge because conventional surgical repair requiring systemic heparinization may be prohibitively high risk. •In this setting, M-TEER under argatroban anticoagulation may serve as a feasible rescue strategy for rapid hemodynamic stabilization. In this setting, M-TEER under argatroban anticoagulation may serve as a feasible rescue strategy for rapid hemodynamic stabilization. Clinical Course and Management Strategy of Acute Severe Primary Mitral Regurgitation Complicated by Clinically Suspected Heparin-Induced Thrombocytopenia The figure summarizes the multidisciplinary decision-making process leading to M-TEER under argatroban anticoagulation, resulting in rapid hemodynamic stabilization without thrombotic or bleeding complications. ACT = activated clotting time; aPTT = activated partial thromboplastin time; HIT = heparin-induced thrombocytopenia; IABP = intra-aortic balloon pump; MR = mitral regurgitation; M-TEER = transcatheter edge-to-edge mitral valve repair. Funding Support and Author Disclosures The authors have reported that they have no relationships relevant to the contents of this paper to disclose.